Presentations and interviews

BioStock Life Science Fall Summit video | Oct 2023

BioStock Investor Meeting Presentation Sep 2023

BioStock Life Science Spring Summit 2023, 31 May 2023

Biostock interviews CEO Pernilla Sandwall, March 27 2023

Biostock presentation Investor summit, March 16 2023

Presentation of the ad hoc observations in the phase 2 study NeoFox, January 2023

BioStock interviews Professor Tommy Andersson and CEO Pernilla Sandwall about the findings and the revised study plan, December 2022

Pernilla Sandwall presents the company at the Biostock life science fall summit where also professor Tommy Andersson explains the unexpected observations, 8 december 2022

BioStock interview with WntResearch’s CEO Pernilla Sandwall, September 28, 2022

CEO Pernilla Sandwall at Biostock Investor Meeting, September 14, 2022

CEO Pernilla Sandwall at BioStock Life Science Spring Summit June 9, 2022

Investor presentation March 2021

See the presentation

”Sitdown” interview with Peter Morsing, CEO

27 February 2019


WntResearch holds presentation at Stockholm Corporate Finance Life Science Seminarium

7 March 2018


Information material presented by acting CEO Ulf Björklund at the extraordinary general meeting

20 September 2017


Presentation at Stockholm Corporate Finance Life Science Seminar

22 March 2017


Presentation at Investor Dagen in Copenhagen

21 March 2017


Presentation at Biotech Showcase in San Francisco 

11 January 2017  



Aktiespararna Stockholm Vasa and Financial Stockholm

25 October at 18:00


Aktiespararna, Malmö Centrum

May 11, 2016

Interview with CEO Henrik Lawaetz

March 16, 2016


Sedermeradagen, Lund

March 16, 2016

Stockholm Corporate Finance, Stockholm

March 10, 2016

Video from presentation of WntResearch at Stockholm Corporate Finance

CEO Henrik Lawaetz and CSO Tommy Andersson presented the company at Stockholm Corporate Finance Life Science & Healthcare Seminar at Operaterrassen in Stockholm, Thursday March 10.


LifeScienceDagen 2016, Gothenburg.

 March 9, 2016

A commentary on the interim Foxy-5 phase 1 study report

The recent publication of an interim report of Foxy-5 clinical Phase 1 study has raised a lot of questions. This has prompted us to write a clarification on how WntResearch values the results obtained so far.


Short congress report 

From AACR.NCI.EORTC Scientific meeting: Molecular Targets and Cancer Therapeutics in cancer, November 5-9, 2015 in Boston, USA with comments from CEO Nils Brünner


Foxy-5 – Preliminary Report: Phase I

Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate Cancer
November 6th, 2015


WntResearch at Sedermeradagen in Lund 26 March 2015

Speaker: Nils Brünner, VD


Annual General Assembly, Malmø, 09.06.15

Speaker: Nils Brünner, CEO